Time course of hemoglobin (Hb) level, serum erythropoietin level (sEpo), and serum transferrin receptor (sTfR) in a patient with pure red cell aplasia (PRCA) responding to treatment.

The patient was treated with erythropoietin at a dose of 150 U/kg per day subcutaneously, 5 days a week; dosage was reduced to 3 weekly administrations when Hb level achieved 12 g/dL, and treatment was discontinued after 8 weeks. Reprinted with permission.151